Nuveen LLC Makes New Investment in Caribou Biosciences, Inc. $CRBU

Nuveen LLC bought a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 330,831 shares of the company’s stock, valued at approximately $302,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Two Sigma Advisers LP grew its position in Caribou Biosciences by 39.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company’s stock worth $2,338,000 after purchasing an additional 416,600 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Caribou Biosciences in the 4th quarter worth about $1,921,000. Two Sigma Investments LP grew its position in Caribou Biosciences by 23.7% in the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company’s stock worth $1,779,000 after purchasing an additional 214,239 shares during the last quarter. Millennium Management LLC grew its position in Caribou Biosciences by 52.9% in the 4th quarter. Millennium Management LLC now owns 859,825 shares of the company’s stock worth $1,367,000 after purchasing an additional 297,351 shares during the last quarter. Finally, Northern Trust Corp grew its position in Caribou Biosciences by 3.4% in the 4th quarter. Northern Trust Corp now owns 714,737 shares of the company’s stock worth $1,136,000 after purchasing an additional 23,531 shares during the last quarter. Institutional investors own 77.51% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Caribou Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 24th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Caribou Biosciences currently has an average rating of “Buy” and a consensus target price of $6.67.

Caribou Biosciences Price Performance

CRBU stock opened at $1.87 on Friday. Caribou Biosciences, Inc. has a 12 month low of $0.66 and a 12 month high of $3.00. The firm has a market cap of $174.13 million, a PE ratio of -1.05 and a beta of 2.54. The firm has a 50 day simple moving average of $1.85 and a 200 day simple moving average of $1.30.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. The business had revenue of $2.67 million during the quarter, compared to the consensus estimate of $1.64 million. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%. As a group, sell-side analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.